Life Sciences Tax Lifecycle: From R&D to Exit Under the One Big Beautiful Bill Act
Life sciences companies navigate a unique gauntlet. Programs pivot, trials fail, and financing windows slam shut without warning. Yet tax decisions made in the scramble of formation echo through every funding round until they crystallize at exit, for better or worse. The One Big Beautiful Bill Act didn’t just adjust rates. It rewired fundamental incentives […]
